Canada: Be Careful What You Wish For: A Canadian Perspective on Direct-to-Consumer Advertising And The ‘Learned Intermediary’ Rule

Last Updated: September 7 2004

By Barry Leon, Esq., and Cynthia Tape, Esq.*

Published in Andrews Litigation Reporter: Drug Recall, June 2004.

"Our medical-legal jurisprudence is based on images of health care that no longer exist." So begins the judgment of the New Jersey Supreme Court in Perez v. Wyeth Laboratories Inc., the one court in the United States to hold that the manufacturer of a prescription drug may not rely on the "learned-intermediary" rule if it engages in direct-to-consumer advertising of that product.1

While no other U.S. court appears to have followed New Jersey’s decision, significant changes in the marketing of prescription drugs and consumer participation in health care decision-making suggest that a re-evaluation of the learned-intermediary rule in Canada may lie ahead.

Rationale for the Learned-Intermediary Rule

Under Canadian law, the general rule is that the manufacturer of a product has a duty to warn the ultimate consumer of any material risks associated with the product’s use. In the case of certain types of products, however, an exemption is granted where a "learned intermediary" inevitably intervenes between the manufacturer and the ultimate consumer. In that situation, "a manufacturer may satisfy its informational duty to the consumer by providing a warning to what the American courts have, in recent years, termed a ‘learned intermediary.’"2

Thus, a prescription drug manufacturer can discharge its duty to warn by informing the prescribing physician (the classic learned intermediary) of the material risks. The rationale for the learned-intermediary rule was explained by the Court of Appeal for Ontario in Buchan v. Ortho Pharmaceutical (Canada) Ltd.:

[P]rescription drugs are more likely to be complex medicines, esoteric in formula and varied in effect and, by definition, are available only by prescription. The prescribing physician is in a position to take into account the propensities of the drug and susceptibilities of his patient. He has a duty of informing himself of the benefits and potential dangers of any medications he prescribes, and of exercising his independent judgment as a medical expert based on his knowledge of the patient and the product. In taking the drug, the patient is expected to, and it can be presumed does, place primary reliance on his doctor’s judgment.3

Exception for Certain Types of Drugs

In keeping with this rationale, the learned-intermediary rule has been applied in the context of prescription drugs and medical devices but not to intermediaries in other contexts.4 The defense may not, however, apply to all prescription drug products.

Buchan involved the adequacy of the warnings given by Ortho Pharmaceutical to consumers and physicians about certain risks associated with an oral contraceptive product. In considering the learned-intermediary rule, the Court of Appeal noted that most jurisdictions in the United States recognized the rule without exception. However, a number of state courts had established an exception in the case of oral contraceptives because those courts considered that type of drug to have "vastly different" characteristics:

The oral contraceptive thus stands apart from other prescription drugs in light of the heightened participation of patients in decisions relating to the use of "the pill"; the substantial risks affiliated with the product’s use; the feasibility of direct warnings by the manufacturer to the user; the limited participation of the physician (annual prescriptions); and the possibility that oral communications between physicians and consumers may be insufficient or too scanty standing alone fully to apprise consumers of the product’s dangers at the time the initial selection of a contraceptive method is made as well as at subsequent points when alternative methods may be considered.5

The Court of Appeal ultimately decided Buchan on the basis that the warning given by Ortho to physicians was inadequate. While it was thus unnecessary to decide whether the manufacturer of an oral contraceptive was under a common-law duty to warn consumers directly, the judge referred to a 1970 advisory report on the safety and efficacy of oral contraceptives and then commented in obiter as follows:

As the advisory committee pointed out, "in prescribing [oral contraceptives], the doctor is usually acting neither to treat nor to prevent a disease. He is prescribing for socioeconomic reasons." Furthermore, unlike the selection of an appropriate drug for the treatment of illness or injury where patient involvement is typically minimal or non-existent, consumer demand for oral contraceptives prompts their use more often than doctors’ advice. The decision to use the pill is one in which consumers are actively involved; more frequently than not, they have made the decision before visiting a doctor to obtain a prescription.

For these reasons, … I am of the view that oral contraceptives bear characteristics distinguishing them from most therapeutic, diagnostic and curative prescription drugs. The rationale underlying the learnedintermediary rule, in my opinion, does not hold up in the case of oral contraceptives.6

Could the Exception Become the Rule?

The reasons expressed by the Court of Appeal in Buchan for acknowledging an exception to the learned-intermediary rule in the case of oral contraceptives might arguably apply to other drugs as well, now more than ever.

The "doctor knows best" paradigm is waning as consumers take a more active interest in health products and health care decision-making. At the same time, pharmaceutical companies are seeking to have more direct marketing contact with potential customers. "Lifestyle" drugs to treat "lifestyle disorders" are reportedly a growth industry.7

In this changing health care environment, courts may begin to apply the commentary in Buchan more widely. This has already happened in one case in the United States — Perez, referred to above — as a result of direct-to-consumer advertising.

In Perez, the New Jersey Supreme Court held that a manufacturer that engages in DTC advertising is not entitled to rely on the learned-intermediary rule.8 The court reviewed the following pillars on which the learnedintermediary doctrine is based and held that none of them applies in today’s health care environment:

• Reluctance to undermine the doctor-patient relationship;

• No need for informed consent in an era of "doctor knows best";

• Inability of a drug manufacturer to communicate with patients; and

• Complexity of the subject matter.

As a result, the Perez court concluded as follows:

The question in this case, broadly stated, is whether our law should follow these changes in the marketplace or reflect the images of the past. We believe that when mass marketing of prescription drugs seeks to influence a patient’s choice of a drug, a pharmaceutical manufacturer that makes direct claims to consumers for the efficacy of its product should not be unqualifiedly relieved of the duty to provide proper warnings of the dangers or side effects of the product. 9

In the United States, direct-to-consumer advertising of prescription products was tightly controlled by the Food and Drug Administration until the late 1990s. Before then, advertising of prescription products (including prescription drugs and medical devices) was permitted under the Food, Drug and Cosmetic Act, but there was a statutory requirement that advertising include information about the product’s potential side effects, contraindications and overall effectiveness.10

While it was feasible to include this information in print media advertising, compliance was practically impossible for broadcast media. The situation changed in the late 1990s when the statutory requirements were relaxed for broadcast advertising.11 As a result, ads for prescription drugs are now commonly seen on U.S. television and are freely transmitted into Canada as well.

In Canada, however, there is a broad prohibition against DTC advertising. Canada’s Food and Drugs Act prohibits the advertising of "any food, drug, cosmetic or device to the general public as a treatment, preventative or cure for any of the diseases, disorders or abnormal physical states referred to in Schedule A."12 Schedule A is a comprehensive list of diseases and abnormal states, including arthritis, cancer, depression, diabetes, epilepsy, heart disease, hyper/hypotension, kidney disease, liver disease, obesity and tumors.

In addition, the regulations of the Food and Drugs Act do not allow prescription drugs to be advertised to the general public, except for representations as to the "brand name, proper name, common name, price and quantity of the drug."13 As a result, the advertising of prescription drugs directly to consumers is constrained.

In recent years, however, Health Canada has been considering whether restrictions on such advertising should be eased, as they have in the United States. In 1999, for instance, the Health Products and Food Branch sought input from stakeholders on the objectives, considerations and policy options relating to DTC advertising of prescription drugs in Canada.14 And studies are being carried out on the impact of DTC advertising on consumers, physicians and the health care system in Canada.15

If the restrictions are relaxed, the consequences of such a change for drug manufacturers may be significant. Direct-to-consumer advertising may be good medicine for pharmaceutical companies’ bottom lines, but Perez may signal that an unexpected and unwelcome side effect could be in store.


1. Perez v. Wyeth Labs. Inc., 734 A.2d 1245 at 1246 (N.J. 1999).

2. Hollis v. Dow Corning Corp., [1995] 4 S.C.R. 634 at 658.

3. Buchan v. Ortho Pharm. (Canada) Ltd. (1986), 54 O.R. (2d) 92 at 103 (C.A.). See also Hollis, supra note 2 at 658, citing Reyes v. Wyeth Labs., 498 F.2d 1264 at 1276 (5th Cir. 1974).

4. See, for example, Bow Valley Husky (Bermuda) Ltd. v. Saint John Shipbuilding Ltd., [1997] 3 S.C.R. 1210 (builder of an oil rig is not a learned intermediary), and Guimond Estate v. Fiberglas Canada Inc., (1999), 207 N.B.R. (2d) 355 (Q.B.), aff’d 221 N.B.R. (2d) 119 (C.A.) (manufacturer could not rely on warnings given to a retailer to satisfy its duty to warn consumers about the health risks of styrene).

5. Buchan, supra note 3 at 104.

6. Buchan, supra note 3 at 122.

7. "The disease-specific characteristics and psychosocial factors associated with lifestyle disorders make them perfectly suited for direct-to-consumer advertising." The Lifestyle Drugs Outlook to 2007: Challenges and opportunities in a high-profile growth market, Reuters Business Insight, New Strategic Management Report, excerpt at

8. The drug at issue was Norplant, a contraceptive surgically implanted under the skin of a patient.

9. Perez, supra note 1 at 1247. The court did not leave pharmaceutical companies completely exposed, however. It held that a manufacturer that has complied with regulatory requirements for drug advertising, labeling and warnings is entitled to a rebuttable presumption that the duty to warn has been appropriately discharged.

10. Food, Drug, and Cosmetic Act, 21 U.S.C. § 352(n); 21 C.F.R. pt. 202.1.

11. See U.S. Department of Health & Human Services, Food and Drug Administration, Guidance for Industry: Consumer-Directed Broadcast Advertisements (August 1999), available at handbook/.

12. Food and Drugs Act, R.S.C. 1985, c. F-27, s. 3(1).

13. Food and Drug Regulations, C.R.C. c. 870, s. C.01.044.

14. See, for example, Discussion Document: Direct-to-Consumer Advertising of Prescription Drugs (Apr. 6, 1999), available at

15. See, for example, B. Mintzes et al., An Assessment of the Health System Impacts of Direct-to-Consumer Advertising of Prescription Medicines (DTCA), available on the Web site of the Centre for Health Services and Policy Research at the University of British Columbia; the executive summary is available at hpru/pdf/dtca-v1-execsum.pdf. See also B. Mintzes et al., How does direct-to-consumer advertising (DTCA) affect prescribing? A survey in primary care environments with and without legal DTCA," 169(5) C.M.A.J. 405 (Sept. 2, 2003).s

* Barry Leon practices business litigation, including class actions, intellectual property litigation, products liability litigation and technology litigation. Cynthia Tape practices intellectual property law and litigation primarily in the field of pharmaceuticals, and food and drug regulatory law. Torys LLP is a U.S.-Canadian business law firm with more than 330 lawyers and offices in New York and Toronto.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.